PURPOSE HER2 is a critical gene that drives various solid tumors in addition to those of
breast cancer. For example, HER2 plays a role in non–small-cell lung cancer (NSCLC) …

Non-small-cell lung cancer (NSCLC) harbouring HER2 alterations is now considered a
distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms …

Oncogenic driver mutations have emerged as major treatment targets for molecular
therapies in a variety of cancers. HER2 positivity has been well-studied in breast cancer, but …

Oncogenic driver mutations identified in non-small cell lung cancer (NSCLC) have triggered
the development of drugs capable of interfering in intracellular signaling pathways involved …

Background: Lung cancer is now the leading cause of cancer mortality worldwide for both
men and women. In non-small cell lung cancer (NSCLC), matching a specifically targeted …

Multiple oncogenic molecular alterations have been discovered that serve as potential drug
targets in non-small cell lung cancer (NSCLC). While the pathogenic and pharmacological …

Background HER2 mutations and amplifications have been identified as oncogenic drivers
in lung cancers. Dacomitinib, an irreversible inhibitor of HER2, EGFR (HER1), and HER4 …

In non-small-cell lung cancer (NSCLC), the identification of oncogenic driver mutations led
to the definition of different clinical entities with different therapeutic opportunities, as …

Since several years targeted therapy has been part of treatment in NSCLC in subsets of
patients with specific genetic alterations. One of these alterations involves HER2, a member …

Background HER2 mutations have been identified as oncogenic drivers in lung cancers and
are found in 1–2% of lung adenocarcinomas. There is, to date, no standard of care for these …